Julie Ehlers - Profile and Journalist Details

Find journalists that align with your industry, location and vision. Unlock Julie Ehlers's full journalist profile, including location, coverage topics, current employer, biography and preferences. Sign up today and start building journalist relationships that fuel your startup's growth.

Get connected with journalists today
Julie Ehlers

Julie Ehlers

Verified

Medical Copy Editor, Haymarket Media

Philadelphia

Final Covers

Strength Training , Health , Fitness

Doesn’t Cover

gaming

Journalist Type

Seniority Positions

Industries

Medium Formats

Content

Total articles 382

  • 177Lu-PSMA-617 Improves Upon Enzalutamide in mCRPC

    By Julie Ehlers| Oncology Nurse Advisor Verified Adding 177Lu-PSMA-617 to enzalutamide improves survival and quality of life in patients with metastatic castration-resistant prostate cancer (mCRPC) who are at risk of early treatment failure with enzalutamide alone, according to research presented at the ASCO Genitourinary Cancers Symposium 2025.1These results come from the phase 2 ENZA-p study (NCT04419402), which enrolled 162 patients with mCRPC who had not received chemotherapy.

    By Julie Ehlers · Oncology Nurse Advisor

    Mar. 13, 2025

  • Burnout Declining Among US Oncology Fellows

    By Julie Ehlers| Gastroenterology Advisor Verified US oncology fellows in training experienced less burnout in 2023 than in 2013, according to research published in JCO Oncology Practice. For this study, US medical oncology fellows taking the ASCO Medical Oncology In-Training Exam were invited to complete an optional post-exam survey that included questions related to professional burnout and well-being. The same questions were asked of 1589 fellows in 2023 and 1345 fellows in 2013.

    By Julie Ehlers · Gastroenterology Advisor

    Feb. 28, 2025

  • 177Lu-PSMA-617 Improves Upon Enzalutamide in mCRPC

    By Julie Ehlers| Oncology Nurse Advisor Verified Adding 177Lu-PSMA-617 to enzalutamide improves survival and quality of life in patients with metastatic castration-resistant prostate cancer (mCRPC) who are at risk of early treatment failure with enzalutamide alone, according to research presented at the ASCO Genitourinary Cancers Symposium 2025.1These results come from the phase 2 ENZA-p study (NCT04419402), which enrolled 162 patients with mCRPC who had not received chemotherapy.

    By Julie Ehlers · Oncology Nurse Advisor

    Mar. 13, 2025

As seen in

Company Info

Haymarket Media

McMahons Point, New South Wales, Australia

'+61 2 8399 7636